New medicines are revolutionizing how we fight disease, but too often patients have to fight to access innovative treatments. As part of the solution to this problem, biopharmaceutical companies are working with insurers to develop new ways to pay for medicines.
Results-based contracts are an innovative approach to paying for medicines that often involve greater risk-sharing among payers and biopharmaceutical companies. They can also vary payment based on how well medicines work in different populations. As a result of these arrangements, payers can make a medicine more accessible to patients and biopharmaceutical companies agree to share the financial risk and be reimbursed based on how well medicines work for patients. And the good news is biopharmaceutical companies and insurers are increasingly pursuing these types of arrangements.
Learn more at www.phrma.org/value-collaborative.
Allyson Funk
Ally is a former senior director of public affairs at PhRMA.
Allyson Funk
More oversight needed of unapproved medicines that threaten patients’ health
What they are saying: Florida Drug Importation Program is Unfeasible and Dangerous
Florida’s importation plan puts patients in danger
Three things to know about the accelerated approval pathway
ICYMI: Antimicrobial resistance spotlighted as growing public health threat
Why drug importation is bad for Americans
PhRMA submits comments on FDA’s proposed rule on drug importation
Drug importation: An old idea that is still a bad idea
What they’re saying: Safety is top concern for recent drug importation proposal
ICYMI: Canadian government, stakeholders voice concerns with drug importation proposals
PhRMA responds to Florida’s request for information on drug importation
PhRMA CEO raises concerns with Florida importation proposal, highlights reforms needed to lower costs for patients
Look at the facts. Drug importation is dangerous.
Why state drug importation pilot programs don’t work
ICYMI: Wall Street Journal highlights dangers of counterfeit medicines entering the United States through drug importation
Securely dispose of your unwanted medicines on National Take Back Day
The Washington Post retracts PhRMA claim in opioid story
PhRMA response to Washington Post and 60 Minutes stories
VIDEO: PhRMA CEO discusses industry response to opioid crisis on Mornings with Maria
Protect your health: Important disaster preparedness tips for Harvey and Irma
PhRMA Supports President’s Commission’s Holistic Approach on Opioid Crisis
Opportunities to build upon enhanced competition for medicines in the marketplace
A critical opportunity to prevent prescription drug abuse
Former law enforcement officials raise concerns with drug importation proposals
The risks of counterfeit imported medicines
Resources for understanding the dangers of drug importation
ICYMI: What the experts are saying about importation
How drug importation schemes could increase U.S. law enforcement burdens
Case Study: How one online pharmacy knowingly endangered U.S. consumers
Fact Check Friday: The truth about drug importation and patient safety
What you don’t know about importation from Canada
Discovery of counterfeit hepatitis C drug is another example of why importation is bad for patients
Why drug importation threatens patient safety
Counterfeit Drugs
Prescription Drug Safety
Importation
Why drug importation threatens patient safety
Why drug importation threatens patient safety